Compare UPWK & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPWK | SPTX |
|---|---|---|
| Founded | 1998 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 929.8M |
| IPO Year | 2018 | 2026 |
| Metric | UPWK | SPTX |
|---|---|---|
| Price | $9.10 | $21.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $9.88 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 2.3M | 188.1K |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $787,784,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.33 | ★ N/A |
| Revenue Growth | ★ 2.40 | N/A |
| 52 Week Low | $7.44 | $15.79 |
| 52 Week High | $22.84 | $28.38 |
| Indicator | UPWK | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 57.21 |
| Support Level | $8.29 | $18.72 |
| Resistance Level | $9.27 | $22.75 |
| Average True Range (ATR) | 0.33 | 1.35 |
| MACD | 0.06 | 0.50 |
| Stochastic Oscillator | 64.48 | 83.49 |
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes and connects businesses with AI-enabled talent across every on-demand work type, including freelance, agency, fractional, and payrolled. The business generates revenue from Talent and Clients across the USA, India, Pakistan, the Philippines and the rest of the world. Maximum revenue of the company is derived from Talent segment.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.